EGFR and neoplasm: Of medical interest, tumor treatment with the chemotherapeutic agent cisplatin, a compound that crosslinks purine bases forming adducts in the DNA preventing its repair in case of mishaps (reviewed in [80]), induced the nuclear localization of the EGFR, increasing DNA-dependent protein kinase (DNA-PK) activity and DNA repair and contributing, in this manner, to cisplatin resistance [81,82].